The Experts below are selected from a list of 321 Experts worldwide ranked by ideXlab platform

Mike Sathekge - One of the best experts on this subject based on the ideXlab platform.

  • Non-oncological applications of RGD-based single-photon Emission Tomography and positron Emission Tomography agents.
    European journal of nuclear medicine and molecular imaging, 2020
    Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike Sathekge
    Abstract:

    Non-invasive imaging techniques (especially single-photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible.

  • Non-oncological applications of RGD-based single-photon Emission Tomography and positron Emission Tomography agents
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike Sathekge
    Abstract:

    Introduction Non-invasive imaging techniques (especially single-photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. Methods and Scope This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Conclusion Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible. Graphical abstract

Thomas Ebenhan - One of the best experts on this subject based on the ideXlab platform.

  • Non-oncological applications of RGD-based single-photon Emission Tomography and positron Emission Tomography agents.
    European journal of nuclear medicine and molecular imaging, 2020
    Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike Sathekge
    Abstract:

    Non-invasive imaging techniques (especially single-photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible.

  • Non-oncological applications of RGD-based single-photon Emission Tomography and positron Emission Tomography agents
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike Sathekge
    Abstract:

    Introduction Non-invasive imaging techniques (especially single-photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. Methods and Scope This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Conclusion Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible. Graphical abstract

Jae Min Jeong - One of the best experts on this subject based on the ideXlab platform.

  • Non-oncological applications of RGD-based single-photon Emission Tomography and positron Emission Tomography agents.
    European journal of nuclear medicine and molecular imaging, 2020
    Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike Sathekge
    Abstract:

    Non-invasive imaging techniques (especially single-photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible.

  • Non-oncological applications of RGD-based single-photon Emission Tomography and positron Emission Tomography agents
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike Sathekge
    Abstract:

    Introduction Non-invasive imaging techniques (especially single-photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. Methods and Scope This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Conclusion Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible. Graphical abstract

Janke Kleynhans - One of the best experts on this subject based on the ideXlab platform.

  • Non-oncological applications of RGD-based single-photon Emission Tomography and positron Emission Tomography agents.
    European journal of nuclear medicine and molecular imaging, 2020
    Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike Sathekge
    Abstract:

    Non-invasive imaging techniques (especially single-photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible.

  • Non-oncological applications of RGD-based single-photon Emission Tomography and positron Emission Tomography agents
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike Sathekge
    Abstract:

    Introduction Non-invasive imaging techniques (especially single-photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. Methods and Scope This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Conclusion Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible. Graphical abstract

Jan Rijn Zeevaart - One of the best experts on this subject based on the ideXlab platform.

  • Non-oncological applications of RGD-based single-photon Emission Tomography and positron Emission Tomography agents.
    European journal of nuclear medicine and molecular imaging, 2020
    Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike Sathekge
    Abstract:

    Non-invasive imaging techniques (especially single-photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible.

  • Non-oncological applications of RGD-based single-photon Emission Tomography and positron Emission Tomography agents
    European Journal of Nuclear Medicine and Molecular Imaging, 2020
    Co-Authors: Thomas Ebenhan, Janke Kleynhans, Jan Rijn Zeevaart, Jae Min Jeong, Mike Sathekge
    Abstract:

    Introduction Non-invasive imaging techniques (especially single-photon Emission Tomography and positron Emission Tomography) apply several RGD-based imaging ligands developed during a vast number of preclinical and clinical investigations. The RGD (Arg-Gly-Asp) sequence is a binding moiety for a large selection of adhesive extracellular matrix and cell surface proteins. Since the first identification of this sequence as the shortest sequence required for recognition in fibronectin during the 1980s, fundamental research regarding the molecular mechanisms of integrin action have paved the way for development of several pharmaceuticals and radiopharmaceuticals with clinical applications. Ligands recognizing RGD may be developed for use in the monitoring of these interactions (benign or pathological). Although RGD-based molecular imaging has been actively investigated for oncological purposes, their utilization towards non-oncology applications remains relatively under-exploited. Methods and Scope This review highlights the new non-oncologic applications of RGD-based tracers (with the focus on single-photon Emission Tomography and positron Emission Tomography). The focus is on the last 10 years of scientific literature (2009–2020). It is proposed that these imaging agents will be used for off-label indications that may provide options for disease monitoring where there are no approved tracers available, for instance Crohn’s disease or osteoporosis. Fundamental science investigations have made progress in elucidating the involvement of integrin in various diseases not pertaining to oncology. Furthermore, RGD-based radiopharmaceuticals have been evaluated extensively for safety during clinical evaluations of various natures. Conclusion Clinical translation of non-oncological applications for RGD-based radiopharmaceuticals and other imaging tracers without going through time-consuming extensive development is therefore highly plausible. Graphical abstract